Relypsa raises first funds under $80m round to progress hyperkalaemia drug
This article was originally published in Scrip
Santa Clara, California-based Relypsa informed the US Securities and Exchange Commission (SEC) on 10 August that the company focused on the development of novel non-absorbed polymeric drugs to treat cardiovascular and renal diseases had raised $49.7 million of a planned $80 million equity funding round.
You may also be interested in...
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.